A preclinical consortium approach for assessing the efficacy of combined anti-CD3 plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD mice
We use cookies to analyze site traffic and to ensure that we give you the best experience on our website. We do not sell data obtained through the use of cookies. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.OkPrivacy policy
